Pharmacogenomics of Antidepressant Response in Children and Adolescents

Inclusion Criteria for Patients: * Receiving treatment in an outpatient, residential, or in-patient setting * Meets DSM-IV diagnostic criteria for at least one of the following disorders: anxiety disorder, depressive disorder, eating disorder, or obsessive-compulsive disorder * Receiving a new prescription for an SSRI or SNRI to treat one of the above disorders * A confirmed diagnosis of a "Suicidal Event" or "Behavioral Activation" or both following SSRI or SNRI exposure of at least 3 days duration * Willing to provide a sample of saliva for DNA analysis * English- or Spanish-speaking Exclusion Criteria for Patients: * Inpatient status IF the enrolling inpatient clinician will not continue to follow the patient for the duration of the study * Sibling that is already enrolled in the study * Imminently suicidal and unable to comply with a no-suicide contract or, in the opinion of the treating clinician, has inadequate family monitoring for suicidality * Acutely psychotic at study entry * A demonstrated lack of benefit from or intolerance to SSRI/SNRI antidepressants, as a class * Receiving treatment with a tricyclic antidepressant (TCA) at study enrollment, with the exception of low doses for enuresis for chronic pain. Patients may receive adjunctive TCA treatment during the study at the clinician's discretion. * Received a monoamine oxidase inhibitor (MAOI), such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate), within the past 30 days * Parasu…